Cutting	O
edge	O
:	O
STAT6-deficient	O
mice	O
have	O
enhanced	O
tumor	O
immunity	O
to	O
primary	O
and	O
metastatic	O
mammary	O
carcinoma	O
.	O

STAT4	B-protein
and	O
STAT6	B-protein
are	O
essential	O
for	O
the	O
development	O
of	O
CD4	O
(	O
+	O
)	O
Th1	O
and	O
Th2	O
development	O
,	O
respectively	O
.	O

Tumor	O
immunologists	O
have	O
hypothesized	O
that	O
Th1	B-cell_type
cells	I-cell_type
are	O
critical	O
in	O
tumor	O
immunity	O
because	O
they	O
facilitate	O
differentiation	O
of	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
which	O
are	O
potent	O
anti-tumor	B-cell_type
effectors	I-cell_type
.	O

We	O
have	O
used	O
STAT4	O
(	O
-/-	O
)	O
and	O
STAT6	O
(	O
-/-	O
)	O
mice	O
to	O
test	O
this	O
hypothesis	O
.	O

BALB/c	O
and	O
knockout	O
mice	O
were	O
challenged	O
in	O
the	O
mammary	O
gland	O
with	O
the	O
highly	O
malignant	O
and	O
spontaneously	O
metastatic	O
BALB/c-derived	O
4T1	O
mammary	O
carcinoma	O
.	O

Primary	O
tumor	O
growth	O
and	O
metastatic	O
disease	O
are	O
reduced	O
in	O
STAT6	O
(	O
-/-	O
)	O
mice	O
relative	O
to	O
BALB/c	O
and	O
STAT4	O
(	O
-/-	O
)	O
mice	O
.	O

Ab	O
depletions	O
demonstrate	O
that	O
the	O
effect	O
is	O
mediated	O
by	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
immunized	O
STAT6	O
(	O
-/-	O
)	O
mice	O
have	O
higher	O
levels	O
of	O
4T1-specific	B-cell_type
CTL	I-cell_type
than	O
BALB/c	O
or	O
STAT4	O
(	O
-/-	O
)	O
mice	O
.	O

Surprisingly	O
,	O
Th1	B-cell_type
or	I-cell_type
Th2	I-cell_type
cells	I-cell_type
are	O
not	O
involved	O
,	O
because	O
CD4	O
depletion	O
does	O
not	O
diminish	O
the	O
anti-tumor	O
effect	O
.	O

Therefore	O
,	O
deletion	O
of	O
the	O
STAT6	B-DNA
gene	I-DNA
facilitates	O
development	O
of	O
potent	O
anti-tumor	O
immunity	O
via	O
a	O
CD4	O
(	O
+	O
)	O
-independent	O
pathway	O
.	O

3	NULL
<	NULL
.	NULL

a	NULL
el	NULL
(	NULL
ap	NULL
)	NULL
D	NULL
3	NULL
Reporter	NULL
Cell	NULL
Lines	NULL
a	NULL
a	NULL
g	NULL
The	NULL
film	NULL
”	NULL
)	NULL
!	NULL

keeps	NULL
growing	NULL
Learn	NULL
more	NULL
Ka	NULL
meJournal	NULL
o	NULL
Cutting	NULL
Edge	NULL
:	NULL
STAT6-Deficient	NULL
Mice	NULL
Have	NULL
i	NULL
‘	NULL
éﬁxlmmunolo	NULL
gy	NULL
Enhanced	NULL
Tumor	NULL
Immunity	NULL
to	NULL
Primary	NULL
and	NULL
Metastatic	NULL
Mammary	NULL
Carcinoma	NULL
dge	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
_	NULL
SUzanne	NULL
Ostrand-Rosenberg	NULL
,	NULL
Michael	NULL
J.	NULL
Grusby	NULL
and	NULL
Virginia	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

K.	NULL
Clements	NULL
J	NULL
Immunol	NULL
2000	NULL
;	NULL
165:6015-6019	NULL
;	NULL
;	NULL
doi	NULL
:	NULL
10.4049/jimmunol.165.11.6015	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/165/11/6015	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
28	NULL
articles	NULL
,	NULL
16	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/165/11/6015.full	NULL
#	NULL
ref-list-	NULL
1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
2000	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
(	NULL
CTIDG	NULL
€	NULL
am	NULL
m	NULL
Cutting	NULL
Edge	NULL
:	NULL
STAT6-Deficient	NULL
Mice	NULL
Have	NULL
Enhanced	NULL
Tumor	NULL
Immunity	NULL
to	NULL
Primary	NULL
and	NULL
Metastatic	NULL
Mammary	NULL
Carcinoma	NULL
'	NULL
Suzanne	NULL
Ostrand-Rosenberg	NULL
,	NULL
``	NULL
*	NULL
Michael	NULL
J.	NULL
Grusby	NULL
,	NULL
``	NULL
and	NULL
Virginia	NULL
K.	NULL
Clements*	NULL
STAT4	NULL
and	NULL
STAT6	NULL
are	NULL
essential	NULL
for	NULL
the	NULL
development	NULL
of	NULL
CD4*	NULL
Th1	NULL
and	NULL
Th2	NULL
development	NULL
,	NULL
respectively	NULL
.	NULL

Tumor	NULL
immunologists	NULL
have	NULL
hypothesized	NULL
that	NULL
Th1	NULL
cells	NULL
are	NULL
critical	NULL
in	NULL
tumor	NULL
immunity	NULL
because	NULL
they	NULL
facilitate	NULL
differentiation	NULL
of	NULL
CD8*	NULL
T	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
potent	NULL
anti-tumor	NULL
effectors	NULL
.	NULL

We	NULL
have	NULL
used	NULL
STAT4~'~	NULL
and	NULL
STAT6_'~	NULL
mice	NULL
to	NULL
test	NULL
this	NULL
hypothesis	NULL
.	NULL

BALB/c	NULL
and	NULL
knockout	NULL
mice	NULL
were	NULL
challenged	NULL
in	NULL
the	NULL
mammary	NULL
gland	NULL
with	NULL
the	NULL
highly	NULL
malignant	NULL
and	NULL
spontaneously	NULL
metastatic	NULL
BALB/c-derived	NULL
4T1	NULL
mammary	NULL
carcinoma	NULL
.	NULL

Primary	NULL
tumor	NULL
growth	NULL
and	NULL
metastatic	NULL
disease	NULL
are	NULL
reduced	NULL
in	NULL
STAT6_'~	NULL
mice	NULL
relative	NULL
to	NULL
BALB/c	NULL
and	NULL
STAT4~'~	NULL
mice	NULL
.	NULL

Ab	NULL
depletions	NULL
demonstrate	NULL
that	NULL
the	NULL
effect	NULL
is	NULL
mediated	NULL
by	NULL
CD8*	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
immunized	NULL
STAT6_'~	NULL
mice	NULL
have	NULL
higher	NULL
levels	NULL
of	NULL
CTL	NULL
than	NULL
BALB/c	NULL
or	NULL
STAT4~'~	NULL
mice	NULL
.	NULL

Surprisingly	NULL
,	NULL
Th1	NULL
or	NULL
Th2	NULL
cells	NULL
are	NULL
not	NULL
involved	NULL
,	NULL
because	NULL
CD4	NULL
depletion	NULL
does	NULL
not	NULL
diminish	NULL
the	NULL
anti-tumor	NULL
effect	NULL
.	NULL

Therefore	NULL
,	NULL
deletion	NULL
of	NULL
the	NULL
STAT6	NULL
gene	NULL
facilitates	NULL
development	NULL
of	NULL
potent	NULL
anti-tumor	NULL
immunity	NULL
via	NULL
a	NULL
CD4	NULL
*-independent	NULL
pathway	NULL
.	NULL

-	NULL
The	NULL
Journal	NULL
of	NULL
Im-munology	NULL
,	NULL
2000	NULL
,	NULL
165	NULL
:	NULL
6015-6019.	NULL
that	NULL
when	NULL
phosphorylated	NULL
by	NULL
Janus	NULL
kinases	NULL
are	NULL
activated	NULL
and	NULL
transported	NULL
to	NULL
the	NULL
nucleus	NULL
where	NULL
they	NULL
regulate	NULL
cyto-kine-induced	NULL
gene	NULL
expression	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

Before	NULL
mid-1999	NULL
,	NULL
production	NULL
of	NULL
IL-4	NULL
,	NULL
an	NULL
essential	NULL
cytokine	NULL
for	NULL
differentiation	NULL
of	NULL
Th2	NULL
cells	NULL
,	NULL
was	NULL
thought	NULL
to	NULL
be	NULL
completely	NULL
dependent	NULL
on	NULL
signaling	NULL
via	NULL
STAT6	NULL
,	NULL
and	NULL
T	NULL
he	NULL
STAT4	NULL
and	NULL
STAT6	NULL
genes	NULL
encode	NULL
transcription	NULL
factors	NULL
*Department	NULL
of	NULL
Biological	NULL
Sciences	NULL
,	NULL
University	NULL
of	NULL
Maryland	NULL
,	NULL
Baltimore	NULL
,	NULL
MD	NULL
21250	NULL
;	NULL
and	NULL
*Department	NULL
of	NULL
Immunology	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
Harvard	NULL
School	NULL
of	NULL
Public	NULL
Health	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
Received	NULL
for	NULL
publication	NULL
August	NULL
2	NULL
,	NULL
2000	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
September	NULL
26	NULL
,	NULL
2000	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
adverfisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
RO1	NULL
CA52527	NULL
(	NULL
to	NULL
S.0.R	NULL
.	NULL
)	NULL

and	NULL
ROL	NULL
AMO171	NULL
(	NULL
to	NULL
M.J.G	NULL
.	NULL
)	NULL

and	NULL
U.S.	NULL
Department	NULL
of	NULL
Defense	NULL
Grant	NULL
DAMD94-1-4323	NULL
(	NULL
to	NULL
S.0.R	NULL
.	NULL
)	NULL

.	NULL

M.J.G	NULL
.	NULL

is	NULL
a	NULL
Scholar	NULL
of	NULL
the	NULL
Leukemia	NULL
and	NULL
Lymphoma	NULL
Society	NULL
.	NULL

?	NULL

Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Suzanne	NULL
Ostrand-Rosenberg	NULL
,	NULL
Department	NULL
of	NULL
Biology	NULL
,	NULL
University	NULL
of	NULL
Maryland	NULL
,	NULL
1000	NULL
Hilltop	NULL
Circle	NULL
,	NULL
Baltimore	NULL
,	NULL
MD	NULL
21250	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
srosenbe	NULL
@	NULL
umbc.edu	NULL
Copyright	NULL
©	NULL
2000	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
early	NULL
studies	NULL
with	NULL
STAT6	NULL
knockout	NULL
(	NULL
STAT6	NULL
``	NULL
~	NULL
)	NULL
``	NULL
mice	NULL
supported	NULL
the	NULL
hypothesis	NULL
that	NULL
STAT6	NULL
'~	NULL
mice	NULL
were	NULL
completely	NULL
deficient	NULL
in	NULL
Th2	NULL
production	NULL
(	NULL
4-7	NULL
)	NULL
.	NULL

However	NULL
,	NULL
more	NULL
recent	NULL
studies	NULL
indicate	NULL
there	NULL
is	NULL
an	NULL
alternative	NULL
pathway	NULL
for	NULL
differentiation	NULL
of	NULL
Th2	NULL
cells	NULL
that	NULL
is	NULL
independent	NULL
of	NULL
STAT6	NULL
(	NULL
8-11	NULL
)	NULL
.	NULL

Despite	NULL
this	NULL
alternative	NULL
pathway	NULL
,	NULL
CD4*	NULL
T	NULL
cell	NULL
differentiation	NULL
in	NULL
STAT6	NULL
'~	NULL
mice	NULL
defaults	NULL
to	NULL
a	NULL
Th1-like	NULL
response	NULL
and	NULL
a	NULL
deficiency	NULL
of	NULL
functional	NULL
Th2	NULL
cells	NULL
(	NULL
10	NULL
,	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

STAT4	NULL
was	NULL
originally	NULL
thought	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
development	NULL
of	NULL
Th1	NULL
cells	NULL
(	NULL
14	NULL
)	NULL
because	NULL
it	NULL
is	NULL
a	NULL
transcriptional	NULL
regulatory	NULL
molecule	NULL
for	NULL
IL-12	NULL
,	NULL
which	NULL
is	NULL
a	NULL
potent	NULL
differentiation	NULL
agent	NULL
for	NULL
Th1	NULL
cells	NULL
(	NULL
15	NULL
)	NULL
.	NULL

However	NULL
,	NULL
recent	NULL
studies	NULL
demonstrate	NULL
there	NULL
are	NULL
both	NULL
STAT4-dependent	NULL
and	NULL
STAT4-independent	NULL
pathways	NULL
for	NULL
the	NULL
development	NULL
of	NULL
Th1	NULL
cells	NULL
.	NULL

The	NULL
STAT4-dependent	NULL
pathway	NULL
involves	NULL
induction	NULL
of	NULL
IL-12	NULL
,	NULL
while	NULL
the	NULL
STAT4-independent	NULL
pathway	NULL
does	NULL
not	NULL
involve	NULL
IL-12	NULL
and	NULL
is	NULL
a	NULL
default	NULL
pathway	NULL
that	NULL
occurs	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
STAT6	NULL
signaling	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Even	NULL
though	NULL
STAT4	NULL
knockout	NULL
(	NULL
STAT4	NULL
~~	NULL
)	NULL
mice	NULL
contain	NULL
an	NULL
alternative	NULL
pathway	NULL
for	NULL
generating	NULL
Th1	NULL
cells	NULL
,	NULL
the	NULL
CD4*	NULL
T	NULL
cell	NULL
response	NULL
in	NULL
these	NULL
mice	NULL
is	NULL
strongly	NULL
skewed	NULL
toward	NULL
a	NULL
Th2	NULL
response	NULL
,	NULL
and	NULL
STAT4	NULL
'~	NULL
mice	NULL
are	NULL
deficient	NULL
for	NULL
Th1	NULL
cells	NULL
.	NULL

Th1	NULL
cells	NULL
are	NULL
generally	NULL
considered	NULL
to	NULL
provide	NULL
``	NULL
help	NULL
``	NULL
to	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
Th2	NULL
cells	NULL
provide	NULL
``	NULL
help	NULL
``	NULL
to	NULL
Ab-producing	NULL
B	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
.	NULL

This	NULL
paradigm	NULL
has	NULL
been	NULL
extended	NULL
to	NULL
tumor	NULL
immunity	NULL
,	NULL
and	NULL
investigators	NULL
have	NULL
proposed	NULL
that	NULL
Th1	NULL
cells	NULL
are	NULL
the	NULL
desired	NULL
CD4	NULL
*	NULL
population	NULL
because	NULL
they	NULL
facilitate	NULL
differentiation	NULL
of	NULL
tumor-specific	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
,	NULL
which	NULL
are	NULL
potent	NULL
anti-tumor	NULL
effectors	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
correlation	NULL
between	NULL
STATA4~'~	NULL
and	NULL
STAT6	NULL
'~	NULL
mice	NULL
and	NULL
deficiencies	NULL
in	NULL
Th1	NULL
and	NULL
Th2	NULL
cells	NULL
,	NULL
respectively	NULL
,	NULL
is	NULL
not	NULL
absolute	NULL
,	NULL
we	NULL
speculated	NULL
that	NULL
these	NULL
mice	NULL
might	NULL
provide	NULL
useful	NULL
information	NULL
on	NULL
the	NULL
roles	NULL
of	NULL
Th1	NULL
and	NULL
Th2	NULL
cells	NULL
in	NULL
anti-tumor	NULL
immunity	NULL
.	NULL

We	NULL
challenged	NULL
BALB/c	NULL
STAT4	NULL
'~	NULL
and	NULL
STAT6	NULL
'~	NULL
mice	NULL
in	NULL
the	NULL
mammary	NULL
gland	NULL
with	NULL
the	NULL
highly	NULL
malignant	NULL
,	NULL
nonimmunogenic	NULL
,	NULL
and	NULL
metastatic	NULL
BALB/c-derived	NULL
4T1	NULL
mammary	NULL
carcinoma	NULL
(	NULL
21-23	NULL
)	NULL
.	NULL

Our	NULL
expectation	NULL
was	NULL
that	NULL
STAT6	NULL
'~	NULL
mice	NULL
would	NULL
have	NULL
enhanced	NULL
anti-tumor	NULL
immunity	NULL
because	NULL
differentiation	NULL
of	NULL
CD4*~	NULL
T	NULL
cells	NULL
would	NULL
be	NULL
skewed	NULL
toward	NULL
a	NULL
Th1	NULL
response	NULL
and	NULL
that	NULL
STAT4	NULL
'~	NULL
mice	NULL
would	NULL
have	NULL
reduced	NULL
anti-tumor	NULL
immunity	NULL
because	NULL
they	NULL
are	NULL
deficient	NULL
for	NULL
Th1	NULL
cells	NULL
.	NULL

We	NULL
observed	NULL
that	NULL
the	NULL
4T	NULL
1	NULL
tumor	NULL
grows	NULL
and	NULL
metastasizes	NULL
less	NULL
in	NULL
STAT6	NULL
'~	NULL
mice	NULL
,	NULL
suggesting	NULL
that	NULL
deletion	NULL
of	NULL
the	NULL
STAT6	NULL
gene	NULL
enhances	NULL
anti-tumor	NULL
immunity	NULL
.	NULL

Surprisingly	NULL
,	NULL
however	NULL
,	NULL
the	NULL
°	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
STAT6	NULL
``	NULL
~	NULL
,	NULL
BALB/c	NULL
mouse	NULL
knocked	NULL
out	NULL
for	NULL
the	NULL
STAT6	NULL
gene	NULL
;	NULL
STAT4	NULL
'~	NULL
,	NULL
BALB/c	NULL
mouse	NULL
knocked	NULL
out	NULL
for	NULL
the	NULL
STAT4	NULL
gene	NULL
;	NULL
Tel	NULL
,	NULL
CD8*	NULL
T	NULL
cytotoxic	NULL
1	NULL
cells	NULL
;	NULL
Te2	NULL
,	NULL
CD8	NULL
``	NULL
T	NULL
cytotoxic	NULL
2	NULL
cells	NULL
;	NULL
4TI	NULL
,	NULL
BALB/c	NULL
mouse	NULL
mammary	NULL
carcinoma	NULL
.	NULL

0022-1767/00/	NULL
$	NULL
02.00	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
6016	NULL
STAT6	NULL
'~	NULL
effect	NULL
is	NULL
independent	NULL
of	NULL
Thl1	NULL
or	NULL
Th2	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
STAT6	NULL
gene	NULL
negatively	NULL
regulates	NULL
tumor	NULL
growth	NULL
via	NULL
a	NULL
CD4*	NULL
T	NULL
cell-independent	NULL
mechanism	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Mice	NULL
and	NULL
tumor	NULL
challenges	NULL
BALB/c	NULL
STAT6	NULL
'~	NULL
(	NULL
5	NULL
)	NULL
and	NULL
STAT4~'~	NULL
(	NULL
14	NULL
)	NULL
mice	NULL
were	NULL
bred	NULL
in	NULL
the	NULL
University	NULL
of	NULL
Maryland	NULL
Baltimore	NULL
County	NULL
(	NULL
UMBC	NULL
)	NULL
Biology	NULL
Department	NULL
animal	NULL
facility	NULL
.	NULL

These	NULL
mice	NULL
were	NULL
generated	NULL
by	NULL
targeted	NULL
disruption	NULL
of	NULL
the	NULL
STAT6	NULL
and	NULL
STAT4	NULL
genes	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
129	NULL
strain	NULL
mice	NULL
.	NULL

Offspring	NULL
were	NULL
backcrossed	NULL
for	NULL
10	NULL
generations	NULL
to	NULL
BALB/c	NULL
mice	NULL
.	NULL

STAT6	NULL
'~	NULL
and	NULL
STAT4~'~	NULL
mice	NULL
have	NULL
no	NULL
detectable	NULL
STAT6	NULL
or	NULL
STAT4	NULL
protein	NULL
,	NULL
respectively	NULL
.	NULL

BALB/c	NULL
mice	NULL
were	NULL
either	NULL
purchased	NULL
from	NULL
The	NULL
Jackson	NULL
Laboratory	NULL
(	NULL
Bar	NULL
Harbor	NULL
,	NULL
ME	NULL
)	NULL
,	NULL
and/or	NULL
bred	NULL
at	NULL
UMBC	NULL
and	NULL
maintained	NULL
in	NULL
accordance	NULL
with	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
guidelines	NULL
for	NULL
the	NULL
humane	NULL
treatment	NULL
of	NULL
laboratory	NULL
animals	NULL
.	NULL

Mice	NULL
were	NULL
challenged	NULL
in	NULL
the	NULL
abdominal	NULL
mammary	NULL
gland	NULL
with	NULL
7	NULL
X	NULL
10°	NULL
wild-type	NULL
4T1	NULL
tumor	NULL
cells	NULL
.	NULL

Primary	NULL
tumors	NULL
at	NULL
the	NULL
site	NULL
of	NULL
injection	NULL
were	NULL
measured	NULL
using	NULL
an	NULL
electronic	NULL
calipers	NULL
and	NULL
tumor	NULL
diameters	NULL
calculated	NULL
as	NULL
the	NULL
square	NULL
root	NULL
of	NULL
the	NULL
length	NULL
X	NULL
width	NULL
of	NULL
the	NULL
tumor	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Number	NULL
of	NULL
clonogenic	NULL
lung	NULL
metastases	NULL
was	NULL
determined	NULL
by	NULL
plating	NULL
dissociated	NULL
lung	NULL
cells	NULL
in	NULL
medium	NULL
supplemented	NULL
with	NULL
6-TG	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Data	NULL
presented	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
primary	NULL
tumor	NULL
challenge	NULL
experiments	NULL
and	NULL
two	NULL
independent	NULL
metastasis	NULL
experiments	NULL
.	NULL

Immunofluorescence	NULL
Immunofluorescence	NULL
staining	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
24	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
percent	NULL
CD4*	NULL
and	NULL
CD8*	NULL
T	NULL
cells	NULL
in	NULL
naive	NULL
and	NULL
immunized	NULL
STAT4-~'~	NULL
,	NULL
STAT6	NULL
'~	NULL
,	NULL
and	NULL
BALB/c	NULL
mice	NULL
,	NULL
splenocytes	NULL
were	NULL
double	NULL
labeled	NULL
for	NULL
CD3	NULL
plus	NULL
CD4	NULL
or	NULL
CD3	NULL
plus	NULL
CD8	NULL
.	NULL

Mice	NULL
were	NULL
immunized	NULL
using	NULL
the	NULL
identical	NULL
schedule	NULL
and	NULL
number	NULL
of	NULL
immunizations	NULL
as	NULL
the	NULL
donors	NULL
for	NULL
effectors	NULL
in	NULL
the	NULL
CTL	NULL
assays	NULL
;	NULL
however	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
not	NULL
from	NULL
the	NULL
same	NULL
animals	NULL
used	NULL
in	NULL
the	NULL
CTL	NULL
assays	NULL
.	NULL

Reported	NULL
values	NULL
for	NULL
percent	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
are	NULL
averages	NULL
from	NULL
at	NULL
least	NULL
five	NULL
animals	NULL
per	NULL
group	NULL
.	NULL

CD4*	NULL
and	NULL
CD8¢	NULL
T	NULL
cell	NULL
depletions	NULL
Mice	NULL
were	NULL
in	NULL
vivo	NULL
depleted	NULL
for	NULL
CD4	NULL
*	NULL
or	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
using	NULL
mAbs	NULL
to	NULL
CD4	NULL
(	NULL
GK	NULL
1.5	NULL
;	NULL
Ref	NULL
.	NULL

25	NULL
)	NULL
or	NULL
CD8	NULL
(	NULL
2.43	NULL
;	NULL
Ref	NULL
.	NULL

26	NULL
)	NULL
on	NULL
days	NULL
-6	NULL
,	NULL
-3	NULL
,	NULL
and	NULL
-1	NULL
,	NULL
and	NULL
one	NULL
to	NULL
two	NULL
times	NULL
a	NULL
week	NULL
thereafter	NULL
,	NULL
where	NULL
day	NULL
0	NULL
is	NULL
the	NULL
day	NULL
of	NULL
tumor	NULL
challenge	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
22	NULL
)	NULL
.	NULL

All	NULL
mice	NULL
were	NULL
checked	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
at	NULL
the	NULL
end	NULL
of	NULL
the	NULL
experiment	NULL
(	NULL
day	NULL
42	NULL
)	NULL
for	NULL
completeness	NULL
of	NULL
depletions	NULL
.	NULL

In	NULL
the	NULL
experiments	NULL
shown	NULL
in	NULL
Figs	NULL
.	NULL

2	NULL
and	NULL
3	NULL
,	NULL
CD4	NULL
and	NULL
CD8	NULL
levels	NULL
in	NULL
depleted	NULL
mice	NULL
were	NULL
<	NULL
1	NULL
%	NULL
,	NULL
except	NULL
for	NULL
one	NULL
of	NULL
the	NULL
CD4-depleted	NULL
mice	NULL
which	NULL
had	NULL
8	NULL
%	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

For	NULL
CTL	NULL
assays	NULL
,	NULL
immunized	NULL
donors	NULL
were	NULL
depleted	NULL
for	NULL
CD4*	NULL
or	NULL
CD8*	NULL
T	NULL
cells	NULL
using	NULL
mAbs	NULL
to	NULL
CD4	NULL
(	NULL
GK1.5	NULL
)	NULL
or	NULL
CD8	NULL
(	NULL
2.43	NULL
)	NULL
before	NULL
the	NULL
last	NULL
immunization	NULL
using	NULL
the	NULL
same	NULL
schedule	NULL
as	NULL
above	NULL
,	NULL
where	NULL
day	NULL
0	NULL
is	NULL
the	NULL
day	NULL
of	NULL
the	NULL
final	NULL
immunization	NULL
and	NULL
spleens	NULL
were	NULL
removed	NULL
on	NULL
day	NULL
5	NULL
.	NULL

Data	NULL
presented	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

CTL	NULL
assays	NULL
CTL	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
27	NULL
)	NULL
with	NULL
the	NULL
following	NULL
modifications	NULL
.	NULL

Target	NULL
cells	NULL
(	NULL
4T1	NULL
and	NULL
melF10	NULL
)	NULL
were	NULL
labeled	NULL
at	NULL
up	NULL
to	NULL
10	NULL
``	NULL
cells/500	NULL
ul	NULL
FCS	NULL
with	NULL
100	NULL
C	NULL
*'Cr	NULL
(	NULL
NEN	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
for	NULL
1.5	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Labeled	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
excess	NULL
PBS	NULL
,	NULL
incubated	NULL
an	NULL
additional	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
,	NULL
and	NULL
used	NULL
at	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
per	NULL
well	NULL
.	NULL

For	NULL
the	NULL
CTL	NULL
experiment	NULL
of	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
splenic	NULL
effector	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
mice	NULL
that	NULL
were	NULL
immunized	NULL
six	NULL
times	NULL
with	NULL
5000	NULL
rad	NULL
irradiated	NULL
5	NULL
X	NULL
10°	NULL
4T1/AYCD80	NULL
(	NULL
24	NULL
)	NULL
plus	NULL
5	NULL
X	NULL
10°	NULL
4TI/SEB	NULL
(	NULL
23	NULL
)	NULL
cells	NULL
.	NULL

The	NULL
first	NULL
immunization	NULL
was	NULL
performed	NULL
on	NULL
day	NULL
1	NULL
,	NULL
and	NULL
subsequent	NULL
immunizations	NULL
on	NULL
days	NULL
16	NULL
,	NULL
28	NULL
,	NULL
35	NULL
,	NULL
49	NULL
,	NULL
and	NULL
62	NULL
(	NULL
approx-imately	NULL
every	NULL
2	NULL
wk	NULL
)	NULL
.	NULL

Spleens	NULL
were	NULL
removed	NULL
5	NULL
days	NULL
after	NULL
the	NULL
last	NULL
immunization	NULL
and	NULL
used	NULL
directly	NULL
in	NULL
the	NULL
assays	NULL
.	NULL

Labeled	NULL
targets	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
indicated	NULL
number	NULL
of	NULL
effector	NULL
cells	NULL
in	NULL
96-well	NULL
round-bottom	NULL
plates	NULL
at	NULL
37°C	NULL
for	NULL
~18	NULL
h.	NULL
Percentage	NULL
cytotoxicity	NULL
=	NULL
[	NULL
(	NULL
cpm	NULL
experimental	NULL
-	NULL
cpm	NULL
spontaneous	NULL
)	NULL
/	NULL
(	NULL
cpm	NULL
total	NULL
-	NULL
cpm	NULL
spontaneous	NULL
)	NULL
]	NULL
X	NULL
100	NULL
%	NULL
.	NULL

Net	NULL
cytotoxicity	NULL
is	NULL
the	NULL
percent	NULL
cytotoxicity	NULL
of	NULL
the	NULL
specific	NULL
targets	NULL
(	NULL
4T1	NULL
)	NULL
minus	NULL
the	NULL
percent	NULL
cytotoxicity	NULL
of	NULL
the	NULL
irrelevant	NULL
targets	NULL
(	NULL
B16	NULL
melF1Q0	NULL
)	NULL
.	NULL

Data	NULL
presented	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
For	NULL
the	NULL
second	NULL
experi-ment	NULL
,	NULL
mice	NULL
were	NULL
immunized	NULL
five	NULL
,	NULL
instead	NULL
of	NULL
six	NULL
,	NULL
times	NULL
.	NULL
)	NULL

An	NULL
additional	NULL
CTL	NULL
experiment	NULL
was	NULL
performed	NULL
using	NULL
splenocytes	NULL
from	NULL
BALB/c	NULL
,	NULL
STAT4	NULL
'~	NULL
,	NULL
and	NULL
STAT6	NULL
'~	NULL
mice	NULL
immunized	NULL
five	NULL
times	NULL
with	NULL
wild-type	NULL
4T	NULL
1	NULL
cells	NULL
(	NULL
same	NULL
schedule	NULL
and	NULL
number	NULL
of	NULL
immunizing	NULL
cells	NULL
as	NULL
above	NULL
.	NULL
)	NULL

Each	NULL
CTL	NULL
experiment	NULL
was	NULL
conducted	NULL
with	NULL
splenic	NULL
effectors	NULL
from	NULL
BALB/c	NULL
,	NULL
STAT4	NULL
'~	NULL
,	NULL
and	NULL
STAT6	NULL
'~	NULL
mice	NULL
that	NULL
were	NULL
immunized	NULL
concurrently	NULL
using	NULL
the	NULL
identical	NULL
immunization	NULL
schedule	NULL
and	NULL
number	NULL
of	NULL
immunizing	NULL
cells	NULL
.	NULL

The	NULL
effectors	NULL
were	NULL
CUTTING	NULL
EDGE	NULL
assayed	NULL
concurrently	NULL
on	NULL
the	NULL
same	NULL
batch	NULL
of	NULL
target	NULL
cells	NULL
prepared	NULL
for	NULL
each	NULL
experiment	NULL
.	NULL

Statistical	NULL
analyses	NULL
A	NULL
Student	NULL
's	NULL
1	NULL
test	NULL
for	NULL
unequal	NULL
variances	NULL
was	NULL
performed	NULL
using	NULL
Microsoft	NULL
Excel	NULL
(	NULL
Redmond	NULL
,	NULL
WA	NULL
)	NULL
to	NULL
determine	NULL
the	NULL
statistical	NULL
significance	NULL
of	NULL
indicated	NULL
data	NULL
.	NULL

Results	NULL
Primary	NULL
tumor	NULL
growth	NULL
is	NULL
reduced	NULL
and	NULL
delayed	NULL
in	NULL
STAT6	NULL
``	NULL
-	NULL
mice	NULL
The	NULL
BALB/c-derived	NULL
4T1	NULL
mouse	NULL
mammary	NULL
carcinoma	NULL
closely	NULL
models	NULL
human	NULL
breast	NULL
cancer	NULL
in	NULL
that	NULL
it	NULL
grows	NULL
progressively	NULL
in	NULL
the	NULL
anatomically	NULL
correct	NULL
site	NULL
(	NULL
mammary	NULL
gland	NULL
)	NULL
and	NULL
spontaneously	NULL
metastasizes	NULL
to	NULL
a	NULL
variety	NULL
of	NULL
target	NULL
organs	NULL
(	NULL
21	NULL
,	NULL
24	NULL
,	NULL
28	NULL
,	NULL
29	NULL
)	NULL
.	NULL

4T1	NULL
is	NULL
highly	NULL
malignant	NULL
in	NULL
that	NULL
as	NULL
few	NULL
as	NULL
7	NULL
X	NULL
10°	NULL
cells	NULL
implanted	NULL
into	NULL
the	NULL
mammary	NULL
gland	NULL
lead	NULL
to	NULL
progressively	NULL
growing	NULL
primary	NULL
and	NULL
metastatic	NULL
tumor	NULL
in	NULL
>	NULL
95	NULL
%	NULL
of	NULL
inoculated	NULL
mice	NULL
.	NULL

4T1	NULL
is	NULL
also	NULL
nonimmunogenic	NULL
in	NULL
that	NULL
immunization	NULL
with	NULL
irradiated	NULL
4T	NULL
1	NULL
cells	NULL
provides	NULL
no	NULL
protection	NULL
against	NULL
wild-type	NULL
tumor	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
STAT4	NULL
and	NULL
STAT6	NULL
genes	NULL
on	NULL
tumor	NULL
growth	NULL
,	NULL
female	NULL
BALB/c	NULL
,	NULL
STAT6	NULL
'~	NULL
,	NULL
and	NULL
STAT4	NULL
'~	NULL
mice	NULL
were	NULL
inoculated	NULL
in	NULL
the	NULL
mammary	NULL
gland	NULL
with	NULL
4T1	NULL
tumor	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
following	NULL
inoculation	NULL
of	NULL
7	NULL
X	NULL
10°	NULL
4T1	NULL
cells	NULL
,	NULL
onset	NULL
of	NULL
primary	NULL
tumor	NULL
growth	NULL
and	NULL
growth	NULL
rate	NULL
are	NULL
slowed	NULL
in	NULL
STAT6	NULL
'~	NULL
mice	NULL
relative	NULL
to	NULL
STAT4	NULL
'~	NULL
or	NULL
wild-type	NULL
BALB/c	NULL
mice	NULL
.	NULL

Therefore	NULL
,	NULL
deletion	NULL
of	NULL
the	NULL
STAT6	NULL
gene	NULL
reduces	NULL
primary	NULL
mammary	NULL
tumor	NULL
growth	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
functional	NULL
STAT6	NULL
gene	NULL
facilitates	NULL
tumor	NULL
cell	NULL
proliferation	NULL
.	NULL

Metastatic	NULL
disease	NULL
is	NULL
reduced	NULL
in	NULL
STAT6	NULL
'~	NULL
mice	NULL
Following	NULL
inoculation	NULL
into	NULL
the	NULL
mammary	NULL
gland	NULL
,	NULL
4T1	NULL
tumor	NULL
cells	NULL
spontaneously	NULL
metastasize	NULL
to	NULL
the	NULL
lungs	NULL
,	NULL
liver	NULL
,	NULL
brain	NULL
,	NULL
lymph	NULL
nodes	NULL
,	NULL
blood	NULL
,	NULL
and	NULL
bone	NULL
marrow	NULL
(	NULL
21	NULL
,	NULL
24	NULL
,	NULL
29	NULL
)	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
metastasis	NULL
varies	NULL
with	NULL
the	NULL
target	NULL
organs	NULL
;	NULL
however	NULL
,	NULL
the	NULL
earliest	NULL
metastases	NULL
are	NULL
found	NULL
in	NULL
the	NULL
lymph	NULL
nodes	NULL
draining	NULL
the	NULL
site	NULL
of	NULL
primary	NULL
tumor	NULL
growth	NULL
and	NULL
the	NULL
lungs	NULL
.	NULL

Within	NULL
2-3	NULL
wk	NULL
of	NULL
inoculation	NULL
into	NULL
the	NULL
mammary	NULL
gland	NULL
,	NULL
~95	NULL
%	NULL
of	NULL
mice	NULL
have	NULL
metastatic	NULL
cells	NULL
in	NULL
their	NULL
lungs	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Because	NULL
4T1	NULL
cells	NULL
are	NULL
6-thioguanine	NULL
resistant	NULL
,	NULL
metastatic	NULL
tumor	NULL
burden	NULL
in	NULL
target	NULL
organs	NULL
can	NULL
be	NULL
accurately	NULL
quantified	NULL
(	NULL
24	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
metastatic	NULL
spread	NULL
is	NULL
affected	NULL
by	NULL
the	NULL
STAT4	NULL
and/or	NULL
STAT6	NULL
genes	NULL
,	NULL
BALB/c	NULL
,	NULL
STAT6	NULL
'~	NULL
,	NULL
and	NULL
STAT4	NULL
'~	NULL
mice	NULL
were	NULL
inoculated	NULL
in	NULL
the	NULL
mammary	NULL
gland	NULL
with	NULL
7	NULL
X	NULL
10°	NULL
4T1	NULL
cells	NULL
,	NULL
mice	NULL
were	NULL
sacrificed	NULL
42	NULL
days	NULL
later	NULL
,	NULL
and	NULL
the	NULL
number	NULL
of	NULL
4T1	NULL
cells	NULL
in	NULL
their	NULL
lungs	NULL
were	NULL
measured	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
metastatic	NULL
cells	NULL
in	NULL
the	NULL
lungs	NULL
of	NULL
BALB/c	NULL
mice	NULL
range	NULL
between	NULL
0	NULL
and	NULL
4	NULL
X	NULL
10°	NULL
per	NULL
mouse	NULL
,	NULL
while	NULL
four	NULL
of	NULL
five	NULL
STAT4	NULL
'~	NULL
mice	NULL
have	NULL
>	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
_	NULL
14	NULL
308	NULL
E	NULL
-e-	NULL
BaLBe	NULL
<	NULL
10	NULL
}	NULL
-©	NULL
2	NULL
8r	NULL
-a-	NULL
stata	NULL
!	NULL

S	NULL
6	NULL
)	NULL
-a	NULL
5	NULL
4	NULL
}	NULL
-	NULL
#	NULL
-	NULL
state	NULL
'	NULL
San	NULL
0	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
Days	NULL
After	NULL
Tumor	NULL
Challenge	NULL
FIGURE	NULL
1	NULL
.	NULL

STAT6	NULL
'~	NULL
mice	NULL
have	NULL
delayed	NULL
and	NULL
reduced	NULL
primary	NULL
mammary	NULL
carcinoma	NULL
growth	NULL
relative	NULL
to	NULL
wild-type	NULL
BALB/c	NULL
or	NULL
STAT4	NULL
'~	NULL
mice	NULL
.	NULL

Mice	NULL
were	NULL
challenged	NULL
in	NULL
the	NULL
mammary	NULL
gland	NULL
with	NULL
7	NULL
X	NULL
10°	NULL
4T1	NULL
mammary	NULL
carcinoma	NULL
cells	NULL
and	NULL
followed	NULL
for	NULL
tumor	NULL
growth	NULL
.	NULL

Numbers	NULL
to	NULL
the	NULL
right	NULL
of	NULL
each	NULL
line	NULL
indicate	NULL
the	NULL
number	NULL
of	NULL
mice	NULL
with	NULL
tumor	NULL
per	NULL
total	NULL
number	NULL
of	NULL
mice	NULL
challenged	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
4	NULL
®	NULL
8	NULL
100k	NULL
n	NULL
Coe	NULL
H	NULL
*	NULL
5	NULL
g	NULL
105	NULL
e	NULL
e	NULL
s	NULL
e	NULL
2	NULL
aoe	NULL
e	NULL
a	NULL
§	NULL
.E	NULL
600	NULL
.	NULL

*	NULL
--	NULL
10	NULL
oe	NULL
.9	NULL
Ma	NULL
5	NULL
E	NULL
.	NULL

®	NULL
8	NULL
®	NULL
9	NULL
5	NULL
104=1	NULL
1	NULL
}	NULL
F	NULL
|	NULL
4	NULL
0	NULL
x0	NULL
é	NULL
x	NULL
x	NULL
x	NULL
x	NULL
A	NULL
X	NULL
R	NULL
&	NULL
-	NULL
o	NULL
&	NULL
&	NULL
6	NULL
&	NULL
§8	NULL
&	NULL
§	NULL
&	NULL
§	NULL
FIGURE	NULL
2	NULL
.	NULL

STAT6	NULL
'~	NULL
mice	NULL
challenged	NULL
with	NULL
4T1	NULL
mammary	NULL
tumor	NULL
cells	NULL
have	NULL
reduced	NULL
metastatic	NULL
disease	NULL
relative	NULL
to	NULL
wild-type	NULL
BALB/c	NULL
or	NULL
STAT4~'~	NULL
mice	NULL
.	NULL

Reduced	NULL
disease	NULL
is	NULL
due	NULL
to	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

Mice	NULL
were	NULL
challenged	NULL
with	NULL
4T1	NULL
tumor	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Four	NULL
weeks	NULL
after	NULL
tumor	NULL
challenge	NULL
,	NULL
mice	NULL
were	NULL
sacrificed	NULL
,	NULL
lungs	NULL
were	NULL
removed	NULL
,	NULL
and	NULL
the	NULL
number	NULL
of	NULL
lung	NULL
metastases	NULL
was	NULL
quantified	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
STAT6	NULL
'~	NULL
mice	NULL
were	NULL
in	NULL
vivo	NULL
depleted	NULL
with	NULL
Abs	NULL
to	NULL
CD4*	NULL
or	NULL
CD8*	NULL
,	NULL
or	NULL
irrelevant	NULL
Abs	NULL
(	NULL
IgG-	NULL
group	NULL
)	NULL
,	NULL
before	NULL
4T1	NULL
challenge	NULL
,	NULL
and	NULL
the	NULL
lungs	NULL
were	NULL
assayed	NULL
on	NULL
day	NULL
42	NULL
.	NULL

The	NULL
number	NULL
of	NULL
clonogenic	NULL
cells	NULL
in	NULL
the	NULL
lungs	NULL
was	NULL
quantified	NULL
using	NULL
the	NULL
6-thioguanine	NULL
resistance	NULL
assay	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Each	NULL
point	NULL
represents	NULL
the	NULL
number	NULL
of	NULL
clonogenic	NULL
metastatic	NULL
cells	NULL
from	NULL
an	NULL
individual	NULL
animal	NULL
.	NULL

The	NULL
CD8-depleted	NULL
STAT6	NULL
'~	NULL
group	NULL
,	NULL
but	NULL
not	NULL
the	NULL
CD4-depleted	NULL
STAT6	NULL
'~	NULL
group	NULL
,	NULL
is	NULL
significantly	NULL
different	NULL
(	NULL
p	NULL
<	NULL
0.01	NULL
)	NULL
from	NULL
the	NULL
undepleted	NULL
STAT6	NULL
'~	NULL
and	NULL
irrelevant	NULL
control	NULL
IgG-depleted	NULL
STAT6	NULL
'~	NULL
groups	NULL
.	NULL

These	NULL
data	NULL
are	NULL
pooled	NULL
from	NULL
two	NULL
experiments	NULL
.	NULL

each	NULL
,	NULL
and	NULL
none	NULL
of	NULL
the	NULL
STAT6	NULL
'~	NULL
mice	NULL
have	NULL
>	NULL
10°	NULL
metastatic	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
STAT6	NULL
'~	NULL
mice	NULL
have	NULL
fewer	NULL
metastatic	NULL
cells	NULL
in	NULL
their	NULL
lungs	NULL
than	NULL
either	NULL
STAT4~'~	NULL
or	NULL
wild-type	NULL
BALB/c	NULL
mice	NULL
,	NULL
suggesting	NULL
that	NULL
expression	NULL
of	NULL
a	NULL
functional	NULL
STAT6	NULL
gene	NULL
favors	NULL
metastatic	NULL
tumor	NULL
growth	NULL
.	NULL

Reduced	NULL
primary	NULL
and	NULL
metastatic	NULL
tumor	NULL
growth	NULL
is	NULL
mediated	NULL
by	NULL
CD8*	NULL
T	NULL
cells	NULL
and	NULL
CD4*	NULL
T	NULL
cells	NULL
are	NULL
not	NULL
involved	NULL
To	NULL
identify	NULL
the	NULL
effector	NULL
cells	NULL
responsible	NULL
for	NULL
the	NULL
reduced	NULL
tumor	NULL
burdens	NULL
of	NULL
STAT6	NULL
'~	NULL
mice	NULL
,	NULL
mice	NULL
were	NULL
in	NULL
vivo	NULL
depleted	NULL
for	NULL
CD4	NULL
*	NULL
or	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
before	NULL
tumor	NULL
inoculation	NULL
into	NULL
the	NULL
mammary	NULL
gland	NULL
.	NULL

Depletions	NULL
were	NULL
initiated	NULL
on	NULL
day	NULL
-6	NULL
before	NULL
tumor	NULL
challenge	NULL
and	NULL
continued	NULL
through	NULL
day	NULL
42	NULL
of	NULL
tumor	NULL
growth	NULL
.	NULL

Primary	NULL
tumor	NULL
growth	NULL
was	NULL
measured	NULL
throughout	NULL
the	NULL
42-day	NULL
period	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
control	NULL
untreated	NULL
BALB/c	NULL
and	NULL
CD8-depleted	NULL
STAT6	NULL
'~	NULL
mice	NULL
have	NULL
rapidly	NULL
and	NULL
progressively	NULL
growing	NULL
primary	NULL
mammary	NULL
tumors	NULL
,	NULL
while	NULL
CD4-depleted	NULL
STAT6	NULL
'~	NULL
and	NULL
control	NULL
IgG-depleted	NULL
STAT6	NULL
'~	NULL
mice	NULL
have	NULL
more	NULL
slowly	NULL
growing	NULL
primary	NULL
tumors	NULL
.	NULL

CD4-and	NULL
CD8-depleted	NULL
STAT6	NULL
'~	NULL
mice	NULL
were	NULL
also	NULL
followed	NULL
for	NULL
meta-	NULL
15¢	NULL
E	NULL
|	NULL
(	NULL
414	NULL
)	NULL
2	NULL
|	NULL
4	NULL
-M-	NULL
BALB/c	NULL
ts	NULL
10	NULL
}	NULL
©	NULL
|	NULL
-e-g	NULL
[	NULL
$	NULL
0	NULL
}	NULL
A	NULL
s-	NULL
-a	NULL
&	NULL
-	NULL
state	NULL
'	NULL
CD8	NULL
5	NULL
[	NULL
E	NULL
-+-	NULL
stAT6	NULL
!	NULL

igo	NULL
*	NULL
o	NULL
0	NULL
_	NULL
10	NULL
20	NULL
30	NULL
40	NULL
-	NULL
50	NULL
Days	NULL
After	NULL
4T1	NULL
Tumor	NULL
Challenge	NULL
FIGURE	NULL
3	NULL
.	NULL

CD8*	NULL
T	NULL
cells	NULL
mediate	NULL
reduced	NULL
primary	NULL
tumor	NULL
growth	NULL
in	NULL
STAT6	NULL
'~	NULL
mice	NULL
.	NULL

Mice	NULL
were	NULL
challenged	NULL
with	NULL
4T1	NULL
tumor	NULL
,	NULL
and	NULL
primary	NULL
tumor	NULL
growth	NULL
was	NULL
monitored	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Some	NULL
groups	NULL
of	NULL
mice	NULL
were	NULL
in	NULL
vivo	NULL
depleted	NULL
with	NULL
Abs	NULL
to	NULL
CD4*	NULL
or	NULL
CD8*	NULL
T	NULL
cells	NULL
,	NULL
or	NULL
irrelevant	NULL
Abs	NULL
(	NULL
IgG-group	NULL
)	NULL
,	NULL
before	NULL
4T1	NULL
challenge	NULL
.	NULL

6017	NULL
static	NULL
disease	NULL
.	NULL

Depletions	NULL
were	NULL
started	NULL
on	NULL
day	NULL
-6	NULL
,	NULL
mice	NULL
were	NULL
inoculated	NULL
with	NULL
4T1	NULL
tumor	NULL
in	NULL
the	NULL
mammary	NULL
gland	NULL
on	NULL
day	NULL
0	NULL
,	NULL
and	NULL
depletions	NULL
were	NULL
continued	NULL
until	NULL
day	NULL
42	NULL
when	NULL
the	NULL
mice	NULL
were	NULL
sacrificed	NULL
and	NULL
the	NULL
number	NULL
of	NULL
clonogenic	NULL
metastatic	NULL
cells	NULL
in	NULL
the	NULL
lungs	NULL
were	NULL
quantified	NULL
by	NULL
the	NULL
6-TG	NULL
assay	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
STAT6	NULL
'~	NULL
mice	NULL
depleted	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
have	NULL
higher	NULL
levels	NULL
of	NULL
metastatic	NULL
tumor	NULL
cells	NULL
than	NULL
nondepleted	NULL
STAT6	NULL
'~	NULL
mice	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
CD4-depleted	NULL
and	NULL
control	NULL
IgG-depleted	NULL
STAT6	NULL
'~	NULL
mice	NULL
have	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
metastatic	NULL
cells	NULL
in	NULL
the	NULL
lungs	NULL
,	NULL
comparable	NULL
to	NULL
nondepleted	NULL
STAT6	NULL
'~	NULL
mice	NULL
.	NULL

Therefore	NULL
,	NULL
depletion	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
CD4*	NULL
T	NULL
cells	NULL
in	NULL
STAT6	NULL
'~	NULL
mice	NULL
,	NULL
negates	NULL
the	NULL
anti-tumor	NULL
effect	NULL
,	NULL
indicating	NULL
that	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
are	NULL
critical	NULL
for	NULL
tumor	NULL
rejection	NULL
and	NULL
that	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
are	NULL
not	NULL
involved	NULL
.	NULL

Tumor-specific	NULL
CD8¢	NULL
CTL	NULL
develop	NULL
in	NULL
STAT6	NULL
``	NULL
~	NULL
mice	NULL
,	NULL
but	NULL
not	NULL
in	NULL
wild-type	NULL
BALB/c	NULL
mice	NULL
The	NULL
results	NULL
of	NULL
Figs	NULL
.	NULL

2	NULL
and	NULL
3	NULL
demonstrate	NULL
that	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
reduced	NULL
primary	NULL
tumor	NULL
growth	NULL
and	NULL
metastases	NULL
in	NULL
STAT6	NULL
'~	NULL
mice	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
difference	NULL
in	NULL
tumor	NULL
susceptibility	NULL
between	NULL
STAT6	NULL
'~	NULL
,	NULL
STAT4	NULL
'~	NULL
,	NULL
and	NULL
BALB/c	NULL
mice	NULL
is	NULL
due	NULL
to	NULL
differential	NULL
activation	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
CTL	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
splenocytes	NULL
from	NULL
immunized	NULL
mice	NULL
and	NULL
``	NULL
'Cr-labeled	NULL
4T1	NULL
cells	NULL
as	NULL
specific	NULL
targets	NULL
and	NULL
B16	NULL
melF10	NULL
melanoma	NULL
cells	NULL
as	NULL
irrelevant	NULL
targets	NULL
.	NULL

In	NULL
initial	NULL
experiments	NULL
,	NULL
BALB/c	NULL
,	NULL
STAT4	NULL
'~	NULL
,	NULL
and	NULL
STAT6	NULL
'~	NULL
mice	NULL
were	NULL
immunized	NULL
with	NULL
irradiated	NULL
wild-type	NULL
4T1	NULL
cells	NULL
.	NULL

Only	NULL
STAT6	NULL
'~	NULL
effectors	NULL
had	NULL
significant	NULL
cytotoxic	NULL
activity	NULL
(	NULL
net	NULL
cytotoxicity	NULL
of	NULL
0	NULL
,	NULL
12	NULL
,	NULL
and	NULL
56	NULL
%	NULL
for	NULL
BALB/c	NULL
,	NULL
STAT4	NULL
'~	NULL
,	NULL
and	NULL
STAT6	NULL
'~	NULL
effectors	NULL
,	NULL
respectively	NULL
,	NULL
at	NULL
a	NULL
ratio	NULL
of	NULL
120:1	NULL
)	NULL
.	NULL

For	NULL
other	NULL
studies	NULL
,	NULL
we	NULL
have	NULL
developed	NULL
4T	NULL
1	NULL
cell-based	NULL
vaccines	NULL
as	NULL
therapy	NULL
agents	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
4T1	NULL
tumors	NULL
in	NULL
wild-type	NULL
BALB/c	NULL
mice	NULL
.	NULL

The	NULL
vaccines	NULL
consist	NULL
of	NULL
wild-type	NULL
4T1	NULL
cells	NULL
trans-fected	NULL
with	NULL
syngeneic	NULL
MHC	NULL
class	NULL
II	NULL
and	NULL
CD80	NULL
genes	NULL
(	NULL
4T1I/AY	NULL
CD80	NULL
)	NULL
(	NULL
24	NULL
)	NULL
or	NULL
Streptococcus	NULL
aureus	NULL
enterotoxin	NULL
B	NULL
gene	NULL
(	NULL
4T1/	NULL
SEB	NULL
)	NULL
(	NULL
23	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
STAT6	NULL
'~	NULL
mice	NULL
respond	NULL
selectively	NULL
to	NULL
the	NULL
vaccines	NULL
,	NULL
BALB/c	NULL
,	NULL
STAT4	NULL
'~	NULL
,	NULL
and	NULL
STAT6	NULL
'~	NULL
mice	NULL
were	NULL
immunized	NULL
with	NULL
4T1/A*/CD80	NULL
plus	NULL
4TI/SEB	NULL
cells	NULL
,	NULL
and	NULL
CTL	NULL
assays	NULL
were	NULL
performed	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
STAT6	NULL
'~	NULL
mice	NULL
have	NULL
strong	NULL
CTL	NULL
activity	NULL
,	NULL
while	NULL
effectors	NULL
from	NULL
STAT4	NULL
'~	NULL
mice	NULL
have	NULL
modest	NULL
activity	NULL
and	NULL
BALB/c	NULL
mice	NULL
have	NULL
minimal	NULL
activity	NULL
.	NULL

Depletion	NULL
of	NULL
CD8	NULL
*	NULL
,	NULL
but	NULL
not	NULL
CD4	NULL
*	NULL
,	NULL
T	NULL
cells	NULL
from	NULL
so	NULL
f	NULL
(	NULL
@	NULL
)	NULL
BALB/c	NULL
10	NULL
%	NULL
so	NULL
|	NULL
.	NULL

(	NULL
b	NULL
)	NULL
stata	NULL
!	NULL

%	NULL
Cytotoxicity	NULL
tem	NULL
.	NULL

68d	NULL
a4i1	NULL
2a	NULL
Effector	NULL
:	NULL
Target	NULL
Ratio	NULL
®	NULL
4T1	NULL
®	NULL
melF10	NULL
FIGURE	NULL
4	NULL
.	NULL

-	NULL
STAT6	NULL
'~	NULL
mice	NULL
have	NULL
higher	NULL
levels	NULL
of	NULL
tumor-specific	NULL
CTL	NULL
following	NULL
immunization	NULL
with	NULL
4T	NULL
1	NULL
tumor	NULL
cells	NULL
than	NULL
BALB/c	NULL
or	NULL
STAT4	NULL
'~	NULL
mice	NULL
.	NULL

BALB/c	NULL
(	NULL
a	NULL
)	NULL
,	NULL
STAT4	NULL
'~	NULL
(	NULL
b	NULL
)	NULL
,	NULL
or	NULL
STAT6	NULL
'~	NULL
(	NULL
c	NULL
)	NULL
mice	NULL
were	NULL
immunized	NULL
with	NULL
irradiated	NULL
4T1	NULL
tumor	NULL
cells	NULL
,	NULL
and	NULL
splenocytes	NULL
were	NULL
tested	NULL
as	NULL
effector	NULL
cells	NULL
against	NULL
*	NULL
``	NULL
Cr-labeled	NULL
4T	NULL
1	NULL
or	NULL
irrelevant	NULL
melF10	NULL
targets	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
6018	NULL
immunized	NULL
STAT6	NULL
'~	NULL
donors	NULL
before	NULL
harvesting	NULL
splenocytes	NULL
for	NULL
CTL	NULL
assays	NULL
,	NULL
eliminates	NULL
4T1-specific	NULL
cytotoxicity	NULL
,	NULL
demonstrating	NULL
that	NULL
the	NULL
CTL	NULL
effect	NULL
is	NULL
CD8	NULL
*	NULL
T	NULL
cell-mediated	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
increased	NULL
CTL	NULL
activity	NULL
in	NULL
4T1-immunized	NULL
STAT6	NULL
'~	NULL
mice	NULL
may	NULL
be	NULL
due	NULL
to	NULL
differences	NULL
in	NULL
quantities	NULL
of	NULL
CD4	NULL
*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
between	NULL
BALB/c	NULL
,	NULL
STAT4	NULL
'~	NULL
,	NULL
and	NULL
STAT6	NULL
'-	NULL
mice	NULL
.	NULL

To	NULL
test	NULL
this	NULL
possibility	NULL
,	NULL
splenocytes	NULL
from	NULL
naive	NULL
and	NULL
immunized	NULL
BALB/c	NULL
,	NULL
STAT4	NULL
'~	NULL
,	NULL
and	NULL
STAT6	NULL
'~	NULL
mice	NULL
were	NULL
stained	NULL
for	NULL
CD3	NULL
¢CD4*	NULL
and	NULL
CD3	NULL
~CD8	NULL
*	NULL
T	NULL
cells	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Percentages	NULL
of	NULL
CD4*	NULL
and	NULL
CD8*	NULL
T	NULL
cells	NULL
in	NULL
naive	NULL
BALB/c	NULL
,	NULL
STAT4	NULL
``	NULL
~	NULL
,	NULL
and	NULL
STAT6	NULL
'~	NULL
mice	NULL
do	NULL
not	NULL
differ	NULL
between	NULL
the	NULL
strains	NULL
(	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
naive	NULL
BALB/c	NULL
,	NULL
STAT4	NULL
'~	NULL
,	NULL
and	NULL
STAT6	NULL
'~	NULL
mice	NULL
:	NULL
24.5	NULL
,	NULL
29.3	NULL
,	NULL
and	NULL
26.9	NULL
%	NULL
,	NULL
respectively	NULL
;	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
:	NULL
9.4	NULL
,	NULL
9.3	NULL
,	NULL
and	NULL
7.8	NULL
%	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
the	NULL
percentages	NULL
of	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
immunized	NULL
BALB/c	NULL
,	NULL
STAT4	NULL
'~	NULL
,	NULL
and	NULL
STAT6	NULL
'~	NULL
mice	NULL
do	NULL
not	NULL
differ	NULL
from	NULL
those	NULL
in	NULL
naive	NULL
mice	NULL
(	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
immunized	NULL
BALB/c	NULL
,	NULL
STAT4	NULL
``	NULL
~	NULL
,	NULL
and	NULL
STAT6	NULL
'~	NULL
mice	NULL
:	NULL
25.0	NULL
,	NULL
28.2	NULL
,	NULL
and	NULL
25.8	NULL
%	NULL
,	NULL
respectively	NULL
;	NULL
CD8*	NULL
T	NULL
cells	NULL
:	NULL
8.1	NULL
,	NULL
8.9	NULL
,	NULL
and	NULL
9.4	NULL
%	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
knockout	NULL
mice	NULL
do	NULL
not	NULL
have	NULL
significantly	NULL
more	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
increased	NULL
tumor-specific	NULL
CTL	NULL
activity	NULL
of	NULL
STAT6	NULL
'~	NULL
mice	NULL
can	NULL
not	NULL
be	NULL
explained	NULL
because	NULL
of	NULL
higher	NULL
quantities	NULL
of	NULL
CD8	NULL
*	NULL
cytotoxic	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
significant	NULL
tumor-specific	NULL
CD8	NULL
*	NULL
CTL	NULL
activity	NULL
develops	NULL
in	NULL
STAT6	NULL
'~	NULL
mice	NULL
,	NULL
but	NULL
does	NULL
not	NULL
develop	NULL
in	NULL
BALB/c	NULL
or	NULL
STATA	NULL
'~	NULL
mice	NULL
,	NULL
even	NULL
when	NULL
the	NULL
genetically	NULL
modified	NULL
tumor	NULL
vaccines	NULL
are	NULL
the	NULL
immunizing	NULL
agent	NULL
.	NULL

Discussion	NULL
Although	NULL
4T1	NULL
tumor	NULL
growth	NULL
and	NULL
metastasis	NULL
are	NULL
rapid	NULL
and	NULL
progressive	NULL
in	NULL
syngeneic	NULL
BALB/c	NULL
mice	NULL
,	NULL
4T1i	NULL
growth	NULL
in	NULL
STAT6	NULL
'~	NULL
BALB/c	NULL
mice	NULL
is	NULL
significantly	NULL
delayed	NULL
and	NULL
reduced	NULL
.	NULL

The	NULL
delayed	NULL
onset	NULL
and	NULL
reduced	NULL
growth	NULL
rate	NULL
of	NULL
primary	NULL
tumor	NULL
and	NULL
large	NULL
reduction	NULL
in	NULL
metastatic	NULL
tumor	NULL
burden	NULL
are	NULL
particularly	NULL
noteworthy	NULL
because	NULL
4T1	NULL
mammary	NULL
carcinoma	NULL
is	NULL
highly	NULL
malignant	NULL
,	NULL
spontaneously	NULL
metastatic	NULL
,	NULL
and	NULL
nonimmunogenic	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Because	NULL
depletion	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
STAT6	NULL
'~	NULL
mice	NULL
restores	NULL
primary	NULL
tumor	NULL
growth	NULL
and	NULL
metastasis	NULL
to	NULL
levels	NULL
of	NULL
wild-type	NULL
BALB/c	NULL
mice	NULL
,	NULL
the	NULL
anti-tumor	NULL
effect	NULL
in	NULL
STAT6	NULL
'~	NULL
mice	NULL
is	NULL
mediated	NULL
by	NULL
T	NULL
lymphocytes	NULL
.	NULL

Surprisingly	NULL
,	NULL
however	NULL
,	NULL
depletion	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
does	NULL
not	NULL
impact	NULL
tumor	NULL
growth	NULL
in	NULL
STAT6	NULL
'~	NULL
mice	NULL
,	NULL
indicating	NULL
that	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
are	NULL
not	NULL
involved	NULL
in	NULL
tumor	NULL
reduction	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
STAT6	NULL
effect	NULL
is	NULL
not	NULL
due	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
tumor-specific	NULL
Th1	NULL
cells	NULL
,	NULL
as	NULL
originally	NULL
hy-pothesized	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
involvement	NULL
of	NULL
Th1	NULL
cells	NULL
is	NULL
also	NULL
supported	NULL
by	NULL
the	NULL
finding	NULL
that	NULL
STAT4	NULL
'~	NULL
mice	NULL
have	NULL
the	NULL
same	NULL
growth	NULL
rate	NULL
of	NULL
primary	NULL
tumor	NULL
and	NULL
metastasis	NULL
formation	NULL
as	NULL
wild-type	NULL
BALB/c	NULL
mice	NULL
.	NULL

If	NULL
Th1	NULL
generation	NULL
limited	NULL
tumor	NULL
growth	NULL
,	NULL
then	NULL
mice	NULL
deficient	NULL
for	NULL
Th1	NULL
cells	NULL
would	NULL
be	NULL
expected	NULL
to	NULL
have	NULL
more	NULL
rapid	NULL
tumor	NULL
growth	NULL
and	NULL
metastasis	NULL
formation	NULL
than	NULL
wild-type	NULL
STAT4*'*	NULL
mice	NULL
.	NULL

If	NULL
preferential	NULL
development	NULL
of	NULL
tumor-specific	NULL
Th1	NULL
cells	NULL
is	NULL
not	NULL
responsible	NULL
for	NULL
enhanced	NULL
tumor	NULL
immunity	NULL
in	NULL
STAT6	NULL
'-	NULL
mice	NULL
,	NULL
why	NULL
does	NULL
deletion	NULL
of	NULL
the	NULL
STAT6	NULL
gene	NULL
have	NULL
such	NULL
a	NULL
profound	NULL
effect	NULL
on	NULL
tumor	NULL
growth	NULL
?	NULL

A	NULL
trivial	NULL
explanation	NULL
is	NULL
that	NULL
the	NULL
STAT6	NULL
'-	NULL
mice	NULL
are	NULL
sufficiently	NULL
genetically	NULL
disparate	NULL
from	NULL
BALB/c	NULL
mice	NULL
that	NULL
the	NULL
4T1	NULL
tumor	NULL
is	NULL
essentially	NULL
an	NULL
allograft	NULL
and	NULL
therefore	NULL
immunogenic	NULL
in	NULL
STAT6	NULL
'~	NULL
mice	NULL
.	NULL

This	NULL
explanation	NULL
is	NULL
unlikely	NULL
for	NULL
at	NULL
least	NULL
two	NULL
rea-sons	NULL
.	NULL

First	NULL
,	NULL
STAT6	NULL
'~	NULL
mice	NULL
have	NULL
been	NULL
backcrossed	NULL
10	NULL
generations	NULL
to	NULL
BALB/c	NULL
mice	NULL
,	NULL
making	NULL
them	NULL
>	NULL
99.99	NULL
%	NULL
BALB/c	NULL
,	NULL
and	NULL
making	NULL
it	NULL
very	NULL
unlikely	NULL
that	NULL
there	NULL
are	NULL
significant	NULL
histocompatibility	NULL
differences	NULL
between	NULL
4T	NULL
1	NULL
tumor	NULL
cells	NULL
and	NULL
STAT6	NULL
'~	NULL
mice	NULL
.	NULL

Second	NULL
,	NULL
because	NULL
the	NULL
STAT4	NULL
'~	NULL
mice	NULL
have	NULL
been	NULL
similarly	NULL
backcrossed	NULL
to	NULL
BALB/c	NULL
,	NULL
if	NULL
reduced	NULL
tumor	NULL
growth	NULL
is	NULL
due	NULL
to	NULL
genetic	NULL
discrepancies	NULL
,	NULL
then	NULL
STAT4	NULL
'~	NULL
mice	NULL
should	NULL
also	NULL
exhibit	NULL
reduced	NULL
tumor	NULL
growth	NULL
;	NULL
however	NULL
,	NULL
their	NULL
pattern	NULL
of	NULL
tumor	NULL
progression	NULL
is	NULL
very	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
wild-type	NULL
BALB/c	NULL
mice	NULL
.	NULL

CUTTING	NULL
EDGE	NULL
Because	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
are	NULL
not	NULL
obviously	NULL
involved	NULL
,	NULL
deletion	NULL
of	NULL
the	NULL
STAT6	NULL
gene	NULL
must	NULL
enhance	NULL
tumor	NULL
immunity	NULL
via	NULL
a	NULL
mechanism	NULL
independent	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

There	NULL
are	NULL
several	NULL
possible	NULL
alternative	NULL
mechanisms	NULL
.	NULL

First	NULL
,	NULL
STAT6	NULL
'~	NULL
mice	NULL
may	NULL
preferentially	NULL
produce	NULL
Tel	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
that	NULL
are	NULL
more	NULL
efficacious	NULL
than	NULL
Tc2	NULL
cells	NULL
in	NULL
reducing	NULL
tumor	NULL
cell	NULL
growth	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
STAT6	NULL
gene	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
a	NULL
signaling	NULL
pathway	NULL
that	NULL
produces	NULL
an	NULL
inhibitor	NULL
that	NULL
blocks	NULL
CD8	NULL
*	NULL
T	NULL
cell-mediated	NULL
anti-tumor	NULL
immunity	NULL
.	NULL

Elimination	NULL
of	NULL
this	NULL
inhibitor	NULL
results	NULL
in	NULL
enhanced	NULL
development	NULL
of	NULL
tumor-specific	NULL
CD8	NULL
*	NULL
T	NULL
effector	NULL
cells	NULL
.	NULL

Third	NULL
,	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
are	NULL
one	NULL
component	NULL
of	NULL
the	NULL
enhanced	NULL
anti-tumor	NULL
effect	NULL
,	NULL
but	NULL
other	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
anti-angiogenic	NULL
factors	NULL
,	NULL
are	NULL
also	NULL
involved	NULL
.	NULL

Inactivation	NULL
of	NULL
the	NULL
STAT6	NULL
gene	NULL
favors	NULL
the	NULL
development	NULL
of	NULL
anti-angiogenic	NULL
mechanisms	NULL
that	NULL
limit	NULL
primary	NULL
tumor	NULL
and	NULL
metastatic	NULL
tumor	NULL
growth	NULL
.	NULL

Therefore	NULL
,	NULL
STAT6	NULL
'~	NULL
mice	NULL
may	NULL
show	NULL
reduced	NULL
tumor	NULL
growth	NULL
due	NULL
to	NULL
immunologic	NULL
and	NULL
nonimmunologic	NULL
mechanisms	NULL
.	NULL

In	NULL
earlier	NULL
studies	NULL
,	NULL
the	NULL
4T1	NULL
vaccines	NULL
(	NULL
4T1/AY/CD80	NULL
plus	NULL
4T1/	NULL
SEB	NULL
)	NULL
have	NULL
shown	NULL
significant	NULL
therapeutic	NULL
efficacy	NULL
in	NULL
wild-type	NULL
BALB/c	NULL
mice	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
,	NULL
and	NULL
in	NULL
vivo	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
depletion	NULL
experiments	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
effect	NULL
is	NULL
at	NULL
least	NULL
partially	NULL
due	NULL
to	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
surprising	NULL
that	NULL
the	NULL
vaccines	NULL
only	NULL
stimulate	NULL
a	NULL
significant	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
response	NULL
in	NULL
STAT6	NULL
'~	NULL
mice	NULL
,	NULL
and	NULL
not	NULL
in	NULL
BALB/c	NULL
mice	NULL
.	NULL

Regardless	NULL
of	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
STAT6	NULL
'-	NULL
mice	NULL
have	NULL
enhanced	NULL
immunity	NULL
,	NULL
the	NULL
reduction	NULL
in	NULL
primary	NULL
tumor	NULL
growth	NULL
and	NULL
metastatic	NULL
disease	NULL
is	NULL
large	NULL
and	NULL
is	NULL
unusual	NULL
in	NULL
that	NULL
knocking	NULL
out	NULL
a	NULL
gene	NULL
results	NULL
in	NULL
a	NULL
gain-of-function	NULL
phenotype	NULL
.	NULL

This	NULL
observation	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
inactivation	NULL
of	NULL
the	NULL
STAT6	NULL
'~	NULL
gene	NULL
might	NULL
enhance	NULL
the	NULL
development	NULL
of	NULL
tumor-specific	NULL
immunity	NULL
and	NULL
facilitate	NULL
tumor	NULL
rejection	NULL
and/or	NULL
limit	NULL
malignant	NULL
cell	NULL
proliferation	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Sandy	NULL
Mason	NULL
for	NULL
her	NULL
excellent	NULL
care	NULL
of	NULL
our	NULL
mouse	NULL
colony	NULL
,	NULL
and	NULL
Dr.	NULL
B.	NULL
Pulaski	NULL
for	NULL
helpful	NULL
discussions	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Thie	NULL
,	NULL
J.	NULL
,	NULL
T.	NULL
Nosaka	NULL
,	NULL
W.	NULL
Thierfelder	NULL
,	NULL
F.	NULL
Quelle	NULL
,	NULL
and	NULL
K.	NULL
Shimoda	NULL
.	NULL

1997	NULL
.	NULL

Jaks	NULL
and	NULL
Stats	NULL
in	NULL
cytokine	NULL
signaling	NULL
.	NULL

Stem	NULL
Cells	NULL
Suppl	NULL
.	NULL

1:105	NULL
.	NULL

2	NULL
.	NULL

Heim	NULL
,	NULL
M.	NULL
1999	NULL
.	NULL

The	NULL
Jak-STAT	NULL
pathway	NULL
:	NULL
cytokine	NULL
signalling	NULL
from	NULL
the	NULL
receptor	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

J.	NULL
Recept	NULL
.	NULL

Signal	NULL
.	NULL

Transduction	NULL
Res	NULL
.	NULL

19:75	NULL
.	NULL

3	NULL
.	NULL

Liu	NULL
,	NULL
K.	NULL
,	NULL
S.	NULL
Gaffen	NULL
,	NULL
and	NULL
M.	NULL
Goldsmith	NULL
.	NULL

1998	NULL
.	NULL

JAK/STAT	NULL
signaling	NULL
by	NULL
cytokine	NULL
receptors	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

10:271	NULL
.	NULL

4	NULL
.	NULL

Shimoda	NULL
,	NULL
K.	NULL
,	NULL
J.	NULL
van	NULL
Deursen	NULL
,	NULL
M.	NULL
Sangster	NULL
,	NULL
S.	NULL
Sarawar	NULL
,	NULL
R.	NULL
Carson	NULL
,	NULL
R.	NULL
Tripp	NULL
,	NULL
C.	NULL
Chu	NULL
,	NULL
F.	NULL
Quelle	NULL
,	NULL
T.	NULL
Nosaka	NULL
,	NULL
D.	NULL
Vagnali	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
.	NULL

Lack	NULL
of	NULL
IL-4-induced	NULL
Th2	NULL
response	NULL
and	NULL
IgE	NULL
class	NULL
switching	NULL
in	NULL
mice	NULL
with	NULL
distrupted	NULL
STAT6	NULL
gene	NULL
.	NULL

Nature	NULL
380:630	NULL
.	NULL

5	NULL
.	NULL

Kaplan	NULL
,	NULL
M.	NULL
,	NULL
U.	NULL
Schindler	NULL
,	NULL
S.	NULL
Smiley	NULL
,	NULL
and	NULL
M.	NULL
Grusby	NULL
.	NULL

1996	NULL
.	NULL

STAT6	NULL
is	NULL
required	NULL
for	NULL
mediating	NULL
responses	NULL
to	NULL
IL-4	NULL
and	NULL
for	NULL
the	NULL
development	NULL
of	NULL
Th2	NULL
cells	NULL
.	NULL

Immunity	NULL
4:313	NULL
.	NULL

6	NULL
.	NULL

Kaplan	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
M.	NULL
Grusby	NULL
.	NULL

1998	NULL
.	NULL

Regulation	NULL
of	NULL
T	NULL
helper	NULL
cell	NULL
differentiation	NULL
by	NULL
STAT	NULL
molecules	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

64:2	NULL
.	NULL

7	NULL
.	NULL

Kuperman	NULL
,	NULL
D.	NULL
,	NULL
B.	NULL
Schofield	NULL
,	NULL
M.	NULL
Wills-Karp	NULL
,	NULL
and	NULL
M.	NULL
Grusby	NULL
.	NULL

1998	NULL
.	NULL

Signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
factor	NULL
6	NULL
(	NULL
STAT6	NULL
)	NULL
-deficient	NULL
mice	NULL
are	NULL
protected	NULL
from	NULL
antigen-induced	NULL
airway	NULL
hyperresponsiveness	NULL
and	NULL
mucus	NULL
production	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187:939	NULL
.	NULL

8	NULL
.	NULL

Finkelman	NULL
,	NULL
F.	NULL
,	NULL
S.	NULL
Morris	NULL
,	NULL
T.	NULL
Orekhova	NULL
,	NULL
M.	NULL
Mori	NULL
,	NULL
D.	NULL
Donaldson	NULL
,	NULL
S.	NULL
Reiner	NULL
,	NULL
N.	NULL
Reilly	NULL
,	NULL
L.	NULL
Schopf	NULL
,	NULL
and	NULL
J	NULL
.	NULL

Urban	NULL
.	NULL

2000	NULL
.	NULL

STAT6	NULL
regulation	NULL
of	NULL
in	NULL
vivo	NULL
IL-4	NULL
responses	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

164:2303	NULL
.	NULL

9	NULL
.	NULL

Kaplan	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Wurster	NULL
,	NULL
S.	NULL
Smiley	NULL
,	NULL
and	NULL
M.	NULL
Grusby	NULL
.	NULL

1999	NULL
.	NULL

STAT6-dependent	NULL
and	NULL
-independent	NULL
pathways	NULL
for	NULL
IL-4	NULL
production	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

163:6536	NULL
.	NULL

10	NULL
.	NULL

Jankovic	NULL
,	NULL
D.	NULL
,	NULL
M.	NULL
Kullberg	NULL
,	NULL
N.	NULL
Noben-Trauth	NULL
,	NULL
P.	NULL
Caspar	NULL
,	NULL
W.	NULL
Paul	NULL
,	NULL
and	NULL
A.	NULL
Sher	NULL
.	NULL

2000	NULL
.	NULL

Single	NULL
cell	NULL
analysis	NULL
reveals	NULL
that	NULL
IL-4	NULL
recpetor/STAT6	NULL
signaling	NULL
is	NULL
not	NULL
required	NULL
for	NULL
the	NULL
in	NULL
vivo	NULL
or	NULL
in	NULL
vitro	NULL
development	NULL
of	NULL
CD4*	NULL
lymphocytes	NULL
with	NULL
a	NULL
Th2	NULL
cytokine	NULL
profile	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

164:3047	NULL
.	NULL

11	NULL
.	NULL

Dent	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
Hu-Li	NULL
,	NULL
W.	NULL
Paul	NULL
,	NULL
and	NULL
L.	NULL
Staudt	NULL
.	NULL

1998	NULL
.	NULL

T	NULL
helper	NULL
type	NULL
2	NULL
inflammatory	NULL
disease	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
interleukin	NULL
4	NULL
and	NULL
transcription	NULL
factor	NULL
STAT6	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95:13823	NULL
.	NULL

12	NULL
.	NULL

Ohmori	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
T.	NULL
Hamilton	NULL
.	NULL

1998	NULL
.	NULL

STAT6	NULL
is	NULL
required	NULL
for	NULL
the	NULL
anti-inflammatory	NULL
activity	NULL
of	NULL
IL-4	NULL
in	NULL
mouse	NULL
peritoneal	NULL
macrophages	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:29202	NULL
.	NULL

13	NULL
.	NULL

Stamm	NULL
,	NULL
L.	NULL
,	NULL
A.	NULL
Raisanen-Sokolowski	NULL
,	NULL
M.	NULL
Okano	NULL
,	NULL
M.	NULL
Russell	NULL
,	NULL
J.	NULL
David	NULL
,	NULL
and	NULL
A.	NULL
Satoskar	NULL
.	NULL

1998	NULL
.	NULL

Mice	NULL
with	NULL
STAT6-targeted	NULL
gene	NULL
disruption	NULL
develop	NULL
a	NULL
Th1	NULL
response	NULL
and	NULL
control	NULL
cutaneous	NULL
leishmaniasis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

161:6180	NULL
.	NULL

14	NULL
.	NULL

Kaplan	NULL
,	NULL
M.	NULL
,	NULL
Y	NULL
.	NULL

Sun	NULL
,	NULL
T.	NULL
Hoey	NULL
,	NULL
and	NULL
M.	NULL
Grusby	NULL
.	NULL

1996	NULL
.	NULL

Impaired	NULL
IL-12	NULL
responses	NULL
and	NULL
enhanced	NULL
development	NULL
of	NULL
Th2	NULL
cells	NULL
in	NULL
STAT4-deficient	NULL
mice	NULL
.	NULL

Nature	NULL
382:174	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

Jacobson	NULL
,	NULL
N.	NULL
,	NULL
S.	NULL
Szabo	NULL
,	NULL
R.	NULL
Weber-Nordt	NULL
,	NULL
Z.	NULL
Zhong	NULL
,	NULL
R.	NULL
Schreiber	NULL
,	NULL
J.	NULL
Darnell	NULL
,	NULL
and	NULL
K.	NULL
Murphy	NULL
.	NULL

1995	NULL
.	NULL

Interleukin	NULL
12	NULL
signaling	NULL
in	NULL
T	NULL
helper	NULL
type	NULL
1	NULL
(	NULL
Th1	NULL
)	NULL
cells	NULL
involves	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
3	NULL
and	NULL
STAT4	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:1755	NULL
.	NULL

Kaplan	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Wurster	NULL
,	NULL
and	NULL
M.	NULL
Grusby	NULL
.	NULL

1998	NULL
.	NULL

A	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
Stat	NULL
)	NULL
4-independent	NULL
pathway	NULL
for	NULL
the	NULL
development	NULL
of	NULL
T	NULL
helper	NULL
typel	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

188:1191	NULL
.	NULL

Constant	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
K.	NULL
Bottomly	NULL
.	NULL

1997	NULL
.	NULL

Induction	NULL
of	NULL
the	NULL
TH1	NULL
and	NULL
TH2	NULL
CD4	NULL
*	NULL
T	NULL
cell	NULL
responses	NULL
:	NULL
alternative	NULL
approaches	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

15:297	NULL
.	NULL

Shurin	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
Lu	NULL
,	NULL
P.	NULL
Kalinski	NULL
,	NULL
A.	NULL
Stewart-Akers	NULL
,	NULL
and	NULL
M.	NULL
Lotze	NULL
.	NULL

1999	NULL
.	NULL

Th1/Th2	NULL
balance	NULL
in	NULL
cancer	NULL
,	NULL
transplantation	NULL
and	NULL
pregnancy	NULL
.	NULL

Springer	NULL
Semin	NULL
.	NULL

Immunopathol	NULL
.	NULL

21:339	NULL
.	NULL

Fallarino	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
T.	NULL
Gajewski	NULL
.	NULL

1999	NULL
.	NULL

Cutting	NULL
edge	NULL
:	NULL
differentiation	NULL
of	NULL
antitumor	NULL
CTL	NULL
in	NULL
vivo	NULL
requires	NULL
host	NULL
expression	NULL
of	NULL
Statl	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

163:4109	NULL
.	NULL

Ostrand-Rosenberg	NULL
,	NULL
S.	NULL
,	NULL
V.	NULL
Gunther	NULL
,	NULL
T.	NULL
Armstrong	NULL
,	NULL
B.	NULL
Pulaski	NULL
,	NULL
M.	NULL
Pipeling	NULL
,	NULL
and	NULL
V.	NULL
Clements	NULL
.	NULL

1999	NULL
.	NULL

Immunologic	NULL
targets	NULL
for	NULL
the	NULL
gene	NULL
therapy	NULL
of	NULL
cancer	NULL
.	NULL

In	NULL
Gene	NULL
Therapy	NULL
of	NULL
Cancer	NULL
.	NULL

E.	NULL
Lattime	NULL
,	NULL
and	NULL
S.	NULL
Gerson	NULL
,	NULL
eds	NULL
.	NULL

Academic	NULL
Press	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
p.	NULL
33	NULL
.	NULL

Aslakson	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
F.	NULL
Miller	NULL
.	NULL

1992	NULL
.	NULL

Selective	NULL
events	NULL
in	NULL
the	NULL
metastatic	NULL
process	NULL
defined	NULL
by	NULL
analysis	NULL
of	NULL
the	NULL
sequential	NULL
dissemination	NULL
of	NULL
subpopulations	NULL
of	NULL
a	NULL
mouse	NULL
mammary	NULL
tumor	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

52:1399	NULL
.	NULL

Pulaski	NULL
,	NULL
B.	NULL
,	NULL
V.	NULL
Clements	NULL
,	NULL
M.	NULL
Pipeling	NULL
,	NULL
and	NULL
S.	NULL
Ostrand-Rosenberg	NULL
.	NULL

2000	NULL
.	NULL

Immunotherapy	NULL
with	NULL
vaccines	NULL
combining	NULL
MHC	NULL
class	NULL
I/CD80*	NULL
tumor	NULL
cells	NULL
with	NULL
IL-12	NULL
reduces	NULL
established	NULL
metastatic	NULL
disease	NULL
and	NULL
stimulates	NULL
immune	NULL
effectors	NULL
and	NULL
monokine-induced	NULL
by	NULL
interferon-y	NULL
.	NULL

Cancer	NULL
Immunol	NULL
.	NULL

Immunother	NULL
.	NULL

49:34	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

6019	NULL
Pulaski	NULL
,	NULL
B.	NULL
,	NULL
D.	NULL
Terman	NULL
,	NULL
S.	NULL
Khan	NULL
,	NULL
E.	NULL
Muller	NULL
,	NULL
and	NULL
S.	NULL
Ostrand-Rosenberg	NULL
.	NULL

2000	NULL
.	NULL

Cooperativity	NULL
of	NULL
SEB	NULL
superantigen	NULL
,	NULL
MHC	NULL
class	NULL
II	NULL
,	NULL
and	NULL
CD80	NULL
in	NULL
immunotherapy	NULL
of	NULL
advanced	NULL
metastases	NULL
in	NULL
a	NULL
clinically	NULL
relevant	NULL
post-operative	NULL
breast	NULL
cancer	NULL
model	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

60:2710	NULL
.	NULL

Pulaski	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
S.	NULL
Ostrand-Rosenberg	NULL
.	NULL

1998	NULL
.	NULL

MHC	NULL
class	NULL
II	NULL
and	NULL
B7.1	NULL
immuno-therapeutic	NULL
cell-based	NULL
vaccine	NULL
reduces	NULL
spontancous	NULL
mammary	NULL
carcinoma	NULL
metastases	NULL
without	NULL
affecting	NULL
primary	NULL
tumor	NULL
growth	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

58:1486	NULL
.	NULL

Wilde	NULL
,	NULL
D.	NULL
,	NULL
P.	NULL
Marrack	NULL
,	NULL
J.	NULL
Kappler	NULL
,	NULL
D.	NULL
Dialynis	NULL
,	NULL
and	NULL
F.	NULL
Fitch	NULL
.	NULL

1983	NULL
.	NULL

Evidence	NULL
implicating	NULL
L3T4	NULL
in	NULL
class	NULL
I	NULL
MHC	NULL
antigen	NULL
reactivity	NULL
:	NULL
monoclonal	NULL
antibody	NULL
GK1.5	NULL
blocks	NULL
class	NULL
II	NULL
MHC	NULL
antigen-specific	NULL
proliferation	NULL
,	NULL
release	NULL
of	NULL
lympho-kines	NULL
,	NULL
and	NULL
binding	NULL
by	NULL
cloned	NULL
murine	NULL
helper	NULL
T	NULL
lymphocyte	NULL
lines	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

131:2178	NULL
.	NULL

Sarmiento	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Glasebrook	NULL
,	NULL
and	NULL
F.	NULL
Fitch	NULL
.	NULL

1980	NULL
.	NULL

IgG	NULL
or	NULL
IgM	NULL
monoclonal	NULL
antibodies	NULL
reactive	NULL
with	NULL
different	NULL
determinants	NULL
on	NULL
the	NULL
molecular	NULL
complex	NULL
bearing	NULL
Lyt2	NULL
antigen	NULL
block	NULL
T	NULL
cell	NULL
mediated	NULL
cytolysis	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
complement	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

125:2665	NULL
.	NULL

Lamousé-Smith	NULL
,	NULL
E.	NULL
,	NULL
V.	NULL
K.	NULL
Clements	NULL
,	NULL
and	NULL
S.	NULL
Ostrand-Rosenberg	NULL
.	NULL

1993	NULL
.	NULL

B	NULL
,	NULL
micro-globulin~'~	NULL
knockout	NULL
mice	NULL
contain	NULL
low	NULL
levels	NULL
of	NULL
CD8	NULL
*	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
that	NULL
mediate	NULL
specific	NULL
tumor	NULL
rejection	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:6283	NULL
.	NULL

Miller	NULL
,	NULL
F.	NULL
,	NULL
B.	NULL
Miller	NULL
,	NULL
and	NULL
G.	NULL
Heppner	NULL
.	NULL

1983	NULL
.	NULL

Characterization	NULL
of	NULL
metastatic	NULL
het-erogencity	NULL
among	NULL
subpopulations	NULL
of	NULL
a	NULL
single	NULL
mouse	NULL
mammary	NULL
tumor	NULL
:	NULL
heterogeneity	NULL
in	NULL
phenotypic	NULL
stability	NULL
.	NULL

Invasion	NULL
Metastasis	NULL
3:22	NULL
.	NULL

Lelekakis	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
Moseley	NULL
,	NULL
T.	NULL
Martin	NULL
,	NULL
D.	NULL
Hards	NULL
,	NULL
E.	NULL
Williams	NULL
,	NULL
P.	NULL
Ho	NULL
,	NULL
D.	NULL
Lowen	NULL
,	NULL
J.	NULL
Javni	NULL
,	NULL
F.	NULL
Miller	NULL
,	NULL
J.	NULL
Slavin	NULL
,	NULL
and	NULL
R.	NULL
Anderson	NULL
.	NULL

1999	NULL
.	NULL

A	NULL
novel	NULL
orthotopic	NULL
model	NULL
of	NULL
breast	NULL
cancer	NULL
metastasis	NULL
to	NULL
bone	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

Metastasis	NULL
17:163	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL

